|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
The manufacture of sterile pharmaceutical products is governed in the European Union by the requirements of EU Good Manufacturing Practice for Medicinal Products. The GMP guide gives very specific details on the environmental and microbial requirements for aseptic processing. However, little or no guidance is given on how to create and maintain the correct level of microbial contamination in the aseptic suite. This article focuses on two important issues - creating and maintaining a spore-free environment and preventing spore contamination that may result from the use of disinfectants.
Control of Bacterial Spores
One of the most difficult requirements in a life science cleanroom is the control of bacterial spores. They can enter the cleanroom on people and on components at a surprisingly high rate. Research has shown that 40 per cent of consumables as they are taken from stores are contaminated with bacterial spores (1). The rest of the study showed that if the transfer disinfection procedure employed comprised of spraying solely with alcohol, only 27.6 per cent of the spores would be removed. The results of the different methods tested are shown in Table 1. Annexe 1 of GMP states that 'transfer of materials into and out of the unit is one of the greatest potential sources of contamination' (2).
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Signant Health Proudly Sponsors “DISORDER: The Rare Disease Film Festival” to Raise Awareness and Hope for Millions of Families Worldwide
PHILADELPHIA, PA –September 30, 2019: There are 7,000 recognized rare
disease conditions that affect between 25 and 30 million people in the
United States alone, and the vast majority are totally unknown in the
community. What if there was a film to bring each of these diseases, and
the people fighting them, into the spotlight?
More info >> |
|
 |
White Papers |
 |
|
Clinical Trial Labelling – More Than Just Labels
Faubel & Co. Nachfolger GmbH
Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
More info >> |
|
 |
Industry Events |
 |
2020 Avoca Quality and Innovation Summit
3-4 June 2020, Amsterdam, The Netherlands
The 2020 Avoca Quality and Innovation Summit will take place 3-4 June
2020, in Amsterdam, The Netherlands.
More info >> |
|
|
